NECLIFE

Healthcare Drug Manufacturers - Specialty & Generic

★ Watchlist ⧉ Add to bucket

₹12.2

-0.16% today · 30d +16.75%

as of 2026-09-04

Price · Daily Candles

Detect candlestick pattern

AI narrative is temporarily unavailable for NECLIFE. The deterministic sections below render from live data.

₹ Latest Earnings · Q ending 2026-03-31

REVENUE

₹0 Cr

-100.0% YoY

NET PROFIT

₹-68 Cr

OPM

-672.1%

-636.3pp YoY

EPS

₹-1.85

Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-153.6% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.

◇ Sector Position

PEERPEROCE %

NECLIFE—-5.0

SUNPHARMA37.5721.44

DIVISLAB89.1821.56

ZYDUSLIFE24.6424.22

+ 2 more peers — sign in to view

ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

SCORE / 100

Overall

6-axis composite of the sections below.

Performance NEUTRAL 40

Valuation — —

Growth DECLINING 26

Profitability LOW 5

Technicals NEUTRAL 65

Risk LOW 90

Key Stats

P/B

0.42

52W HIGH

₹22.4

OFF HIGH

-45.54%

MKT CAP

₹235 Cr

◉ Active Signals

MACDBullish0.1034

RSI(14)Neutral59.16

⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold NECLIFE and at what entry.